Survival Outcomes for Patients With Clinical Complete Response After Neoadjuvant Chemotherapy: Is Omitting Surgery an Option?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Surgery
Link
http://link.springer.com/content/pdf/10.1245/s10434-019-07534-1.pdf
Reference25 articles.
1. Criscitiello C, Golshan M, Barry WT, Viale G, Wong S, Santangelo M, Curigliano G. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: a meta-analysis. Eur J Cancer. 2018;97:1–6.
2. Choi J, Laws A, Hu J, Barry W, Golshan M, King T. Margins in breast-conserving surgery after neoadjuvant therapy. Ann Surg Oncol. 2018;25:3541–7.
3. Rea D, Tomlins A, Francis A. Time to stop operating on breast cancer patients with pathological complete response? Eur J Surg Oncol. 2013;39:924–30.
4. van la Parra RF, Kuerer HM. Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials. Breast Cancer Res. 2016;18:28.
5. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85.
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A multidisciplinary team and patient perspective on omission of surgery after neoadjuvant systemic therapy for early breast cancer: A European Society of Surgical Oncology (ESSO) Research Academy survey;European Journal of Surgical Oncology;2024-10
2. Omission of breast surgery in selected breast cancer patients with excellent response to neoadjuvant systemic therapy;European Journal of Surgical Oncology;2024-06
3. Omission of Breast Surgery in Exceptional Responders;Clinical Breast Cancer;2024-06
4. 89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study;Cancers;2023-10-13
5. Accuracy of core biopsy image-guided post-neoadjuvant chemotherapy breast to predict pathologic complete response;Tumors of female reproductive system;2022-12-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3